FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate ‌for up to $3 billion from U.S. biotech firm ‌Synnovation Therapeutics, adding a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results